Literature DB >> 19519461

Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery.

Joseph P Marino1.   

Abstract

Soluble epoxide hydrolase (sEH) is a cross-functional target, with the potential for therapeutic utility in the areas of hypertension, inflammation, and organ-protection. Promising target validation has emerged around soluble epoxide hydrolase in recent years which suggests that small molecule inhibitors may have utility in cardio protection, glucose regulation, hypertension, inflammation, and organ protection. Based on the diversity of chemical classes of sEH inhibitors reported in the literature, there exists a real opportunity to definitively determine the best therapeutic utility for an sEH inhibitor. Recent advances in target validation and tool compounds from medicinal chemistry efforts will be described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519461     DOI: 10.2174/156802609788340805

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  28 in total

Review 1.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

Review 2.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

Review 3.  Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease.

Authors:  Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Congest Heart Fail       Date:  2011-01-27

Review 4.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

5.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

6.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

7.  Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase.

Authors:  Rebecca L Charles; Olena Rudyk; Oleksandra Prysyazhna; Alisa Kamynina; Jun Yang; Christophe Morisseau; Bruce D Hammock; Bruce A Freeman; Philip Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 8.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

9.  Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.

Authors:  Yingmei Liu; Xiaodan Lu; Sinh Nguyen; Jean L Olson; Heather K Webb; Deanna L Kroetz
Journal:  Mol Pharmacol       Date:  2013-10-03       Impact factor: 4.436

Review 10.  Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Authors:  J D Imig
Journal:  Adv Pharmacol       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.